New Survey Finds Alzheimer’s Disease a “National Priority,”
with Voter Support Across Party Lines for Congressional Action
and Faster FDA Review of New Therapies

– Survey also finds concern over cost of care and
strong voter willingness to make Alzheimer’s an issue at the polls –

Washington, DC, September 24, 2009 – A new voter survey sponsored by the
ACT-AD Coalition (Accelerate Cure/Treatments for Alzheimer's Disease) finds that
three-quarters of Americans nationwide and across party lines say it is personally
important to them to find a cure or to prevent Alzheimer’s disease, while a similar
proportion of the national electorate say they look to Congress to make it “a national
priority” to speed up the Food and Drug Administration’s (FDA) review process in
specific ways for therapies that slow, halt or reverse the disease. Voters in large
numbers also said that they would not be able to cover the personal cost of
Alzheimer’s care and that they were ready to reward or punish elected officials at the
polls based on their willingness to act on Alzheimer’s now.

The survey was conducted jointly by the bipartisan team of Lake Research Partners
(D) and American Viewpoint (R). Findings were presented today at the Rock Stars
of Science Capitol Hill Briefing, sponsored by Geoffrey Beene Gives Back®,
Research!America, Alzheimer Association, Wyeth, and Elan; and made possible
with the cooperation of The Congressional Biomedical Research Caucus and the
Alzheimer's Caucus. The briefing united leaders in medical research including the
Director of the National Institutes of Health, Francis S. Collins, MD, PhD, and rock
star Joe Perry from Aerosmith, to rally lawmakers to increase funding for medical
research priorities like Alzheimer’s, cancer, HIV/AIDS and genomics.

According to Celinda Lake, President of Lake Research Partners, “There is clear
voter support for action on Alzheimer’s Disease. This survey sends a message to
elected officials that Alzheimer’s has captured the nation’s attention, and that it may
prove to be an important electoral issue.”

Dan Perry, President of ACT-AD, a coalition of national organizations seeking to
accelerate development of potential cures and treatments for Alzheimer’s, believes
that the survey reflects “the beginning of an Alzheimer’s challenge from the
American voter. We are on the verge of becoming the next generation of Alzheimer’s
casualties, and yet we have access to the same number of treatments to slow or stop
the disease that our parents and grand parents had – none. Add to this treatment
vacuum the fact that the recession leaves Americans with lower personal savings and
a near-bankrupt healthcare system that is ill-prepared to manage the coming
Alzheimer’s explosion. It should come as no surprise that Americans are telling their representatives to find answers to this problem before it is too late.”

**Survey Findings**

According to the survey, voters nationwide and across the political spectrum believe:

Alzheimer’s is a personal and national priority.

- 76 percent of voters nationwide say it is personally important to find a cure for Alzheimer’s and 77 percent believe it is personally important to prevent Alzheimer’s disease. Sentiment is similar across party lines.
- 79 percent want Congress to make it “a national priority” to speed up the FDA’s review process for therapies that slow, halt or reverse the disease.

FDA review policy on Alzheimer’s should reflect this priority.

In the past, the FDA has accelerated its review programs for life threatening diseases like HIV/AIDS and cancer in order to bring urgently needed therapies to patients without sacrificing safety. The survey suggests that American voters now support the same priorities for Alzheimer’s therapies.

- 47 percent of voters nationwide think the FDA should make all possible Alzheimer’s treatments available and allow patients and doctors to decide about risks and benefits, and another 28 percent believe promising drugs for Alzheimer’s deserve the same priority status and fast track review by the FDA as promising drugs for other life-threatening diseases.
- A minority of 15 percent think the FDA should continue to use current procedures of delaying a therapy until it is determined to be completely safe.

Without treatment breakthroughs, Americans cannot cover the cost of Alzheimer’s care.

- 56 percent of voters nationwide said that they are not confident that they would be able to cover the cost of long-term Alzheimer’s care if they or a loved one were diagnosed, with over a third (35 percent) saying they are not at all confident about covering the cost.

Financial assistance will be needed to pay for Alzheimer’s.

- 72 percent strongly favor expanding Medicare coverage to include Alzheimer’s therapies and services in non-traditional settings like the patient’s home.
- 71 percent strongly favor tax deductions for long term care insurance.
- 68 percent strongly support allowing parents under 65 who have been diagnosed with Alzheimer’s to be claimed as dependents by their children.
- 63 percent strongly support tax incentives to caregivers whose parents have Alzheimer’s.
American voters across party lines are ready to make Alzheimer’s drug review an issue at the polls.

- 63 percent would be more likely to vote for a political candidate who is in favor of urging the FDA to speed up their review of therapies that will slow or reverse Alzheimer’s. Forty-nine percent would be less likely to vote for a candidate who came out against urging the FDA to speed up their review of therapies that slow or reverse Alzheimer’s.

“Congressional efforts such as The Senate Subcommittee on Aging, as well as FDA leaders, have worked with the Alzheimer’s community very closely in recent years to explore a national response,” commented Perry. “But the lack of real voter demand has allowed these initiatives to lag. That so many voters across the country and across the political spectrum now see Alzheimer’s as a priority may mean that this disease finally has the kind of momentum that our leaders must respond to.”

About the Survey
Lake Research Partners and American Viewpoint designed and administered this survey, which was conducted by phone using professional interviewers. The survey reached a total of 2,600 likely voters. The survey was comprised of a base sample of 1,000 likely voters nationwide, oversamples of 600 likely California voters, 500 likely Connecticut voters and 500 likely Michigan voters. In the combined totals, respondents in the California, Connecticut and Michigan oversamples were weighted down to reflect their actual proportion in the population. The survey was conducted from June 3 – 14, 2009.

Telephone numbers were drawn from a random digit dialing (RDD) sample. Data were weighted slightly by gender, party identification, age, education, and region to reflect the attributes of this universe. The margin of error for the full sample is +/- 1.9%.

About ACT-AD
ACT-AD is a growing coalition of more than 50 national organizations representing patients, providers, caregivers, consumers, older Americans, researchers and employers seeking to accelerate development of potential cures and treatments for Alzheimer's. The Coalition is directed by an Advisory Council made up of representatives from Alliance for Aging Research (AAR), Alzheimer's Foundation of America (AFA), American Society on Aging (ASA), National Alliance for Caregiving (NAC), National Association of Area Agencies on Aging (n4a), National Consumers League (NCL), Research!America, and the Society for Women’s Health Research. The Coalition is supported by educational grants from Wyeth, Elan, Pfizer, Eli Lilly, and Medivation.
About Lake Research Partners
Lake Research Partners is a national public opinion and political strategy research firm founded by Celinda Lake in 1995. The firm quickly expanded to become Lake Snell Perry Mermin and Associates, and in 2005 continued to grow through a merger with Decision Research. Our principals are leading information and political campaign strategists, serving as tacticians and senior advisors to a wide range of advocacy groups, labor unions, non-profits, government agencies, companies and foundations, as well as dozens of elected officials at all levels of the electoral process. The firm is national in scope, with offices in Washington, DC, New York, and California, and senior staff located in Washington, Oregon, and Virginia.

About American Viewpoint
American Viewpoint, a national respected public opinion research company founded by Linda A. DiVall in 1985. In the past 25 years, we have conducted research and provided strategic advice to political candidates at every level in every region of the country. Our corporate and association experience encompasses numerous policy areas including health care, transportation, environmental, conservation, energy, women’s issues and others. Together, our team of professionals have over 150 years of political and research experience.

Media Contact:
Harry Wade
917-482-9057
Harry.wadenyc@yahoo.com

###